This paper investigated if somatic copy number alterations identified by whole exome sequencing (WES) of formalin-fixed paraffin-embedded (FFPE) specimens of castration-resistant prostate cancer (CRPC) metastasis could be validated by fluorescent in situ hybridization (FISH) in the same specimens and found by FISH in an additional 137 specimens in a prostate cancer progression cohort.
Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer.
Menon R, Deng M, Rüenauver K, Queisser A, Peifer M, Offermann A, Boehm D, Vogel W, Scheble V, Fend F, Kristiansen G, Wernert N, Oberbeckmann N, Biskup S, Rubin MA, Shaikhibrahim Z, Perner S
Purpose
Conclusion
Three chromosome amplifications and seven deletions were found in at least three of the five CPRC cases. FISH confirmed deletion of PTEN and NKX3.1 and amplification of AR and cMYC among some of these specimens and in a prostate cancer progression cohort, but results by WES and FISH from the same specimens were not directly compared. Although 26 single nucleotide variants (SNVs) were identified in four or more of the five specimens, none of these variants were confirmed by Sanger sequencing
Studies (1)
Purpose
This study investigated if somatic copy number alteration identified by WES of FFPE specimens of CRPC metastasis could be validated by fluorescent in situ hybridization in the same specimens and 137 specimens in a prostate cancer progression cohort. FFPE specimens of CRPC metastasis from kidney, lung, rectum, and stomach and matched normal adjacent specimens were obtained by unspecified methods. DNA was extracted from areas with >80% tumor content using the RecoverAll™ Total Nucleic Acid Isolation Kit. Sequencing libraries were constructed using the SOLiD precapture library preparation kit and sequenced with SureSelect Human Whole Exome Kit. FISH and Sanger sequencing were used to validate sequencing results.
Summary of Findings
Greater than 50X coverage was obtained from all specimens. A comparison of tumor and normal adjacent specimens led to the identification of copy number amplifications in chromosomes 8q12.1–q24.21, 17q24.2–25.3, and Xp22.2–p22.11 and deletions in chromosome 8p22–p22.2, 11q22.3–23.3, 16q12.2–24.2, 17p13.2–12, 18q12.2–23, 19q13.11–13.3, and 22q12.2–13.32 in three or more of the five cases. This included amplification of the AR coactivator gene NCOA2 as well as TERF1, RPL7, STAU2, UBE2W, COX6C, PIK3CA, HOXA3, AR, and GRHL2 genes and deletions of the tumor suppressor genes RB1, HSD17B2, HSDL1, BIN3, CHMP7, LOXL2 NT5E, PTEN, TP53, and FUT10. Importantly, many of these genes have also been identified using frozen CRPC specimens in independent studies. FISH confirmed deletion of PTEN and NKX3.1 and amplification of AR and cMYC among some of these specimens and in a prostate cancer progression cohort, but results by WES and FISH from the same specimens were not directly compared. Although 26 SNVs were identified in four or more of the five specimens, none of these variants were confirmed by Sanger sequencing.
Biospecimens
TissueColorectalTissueKidneyTissueStomachTissueLungTissueProstatePreservation Types
FormalinDiagnoses
NeoplasticCarcinomaNeoplasticNormal AdjacentPlatforms
DNANext generation sequencingDNADNA sequencingDNAFISHPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Next generation sequencing Specific Technology platform FISHSanger sequencing